Sylentis Company Profile
Founded in 2006 as a spin-off from Grupo Zeltia subsidiary Genomica, S.A.U., Sylentis is a subsidiary of Grupo Zeltia and a pioneer in Spain in the search for new therapies based on interference RNA (RNAi). The company aims to design effective short interfering RNAs (siRNAs) using bioinformatic programs such as SIRFINDER(R), which optimizes the design of siRNAs with pharmacological potential.
News Articles
None
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Founded in 2006 as a spin-off from Grupo Zeltia subsidiary Genomica, S.A.U., Sylentis is a subsidiary of Grupo Zeltia and a pioneer in Spain in the search for new therapies based on interference RNA (...
Founded in 2006 as a spin-off from Grupo Zeltia subsidiary Genomica, S.A.U., Sylentis is a subsidiary of Grupo Zeltia and a key player in the search for new therapies based on interference RNA (RNAi)....
Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of...
More Information about "Sylentis" on BioPortfolio
We have published hundreds of Sylentis news stories on BioPortfolio along with dozens of Sylentis Clinical Trials and PubMed Articles about Sylentis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sylentis Companies in our database. You can also find out about relevant Sylentis Drugs and Medications on this site too.
